Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone
| Autor: | David, Aguiar-Bujanda, Ignacio, Llorca-Mártinez, José C, Rivero-Vera, María J, Blanco-Sánchez, Pedro, Jiménez-Gallego, Marta, Mori-De Santiago, Miguel A, Limeres-Gonzalez, José C, Cabrera-Marrero, María, Hernández-Sosa, Saray, Galván-Ruíz, Samuel, Hernández-Sarmiento, Salvador, Saura Grau, Uriel, Bohn-Sarmiento |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Aged 80 and over Male Lymphoma B-Cell Marginal Zone Middle Aged Antibodies Monoclonal Murine-Derived Treatment Outcome Stomach Neoplasms Vincristine Antineoplastic Combined Chemotherapy Protocols Humans Prednisone Female Rituximab Cyclophosphamide Aged Follow-Up Studies Neoplasm Staging Retrospective Studies |
| Zdroj: | Hematological oncology. 32(3) |
| ISSN: | 1099-1069 |
| Popis: | There is no standard treatment for patients with gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) who are resistant to, or ineligible for, anti-Helicobacter pylori (anti-HP) therapy. In this study, we investigated the activity of the rituximab, cyclophosphamide, vincristine and prednisone (R-CVP) regimen in patients with gastric MALT lymphoma. Patients were included provided they had untreated gastric MALT lymphoma (except for anti-HP therapy) and were resistant to, or ineligible for, anti-HP therapy. Treatment plan consisted of six to eight 21-day cycles of the R-CVP chemotherapy regimen. Toxicity, response, relapse and survival were evaluated. Twenty patients (12 women and 8 men) were included in the analyses with median age of 59 years. Thirteen patients (65%) had stage I tumours, and seven patients (35%) had stages II-IV tumours. The overall response rate was 100%, with 19 (95%) complete responses and one (5%) partial response. Regimen toxicity was mild and mainly hematological, and no cases of gastric bleeding or perforation occurred. After a median follow-up of 56.3 months, three patients had relapsed, and 19 patients remained alive (specific lymphoma survival 100%), of whom 17 had no evidence of disease. In our experience, the R-CVP regimen is a well-tolerated and effective treatment for patients with gastric MALT lymphoma who are resistant to, or ineligible for, anti-HP therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text